Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan + docetaxel
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Irinotecan + docetaxel is a combination chemotherapy regimen used primarily in the treatment of advanced solid tumors, including esophageal cancer and other malignancies. Irinotecan is a topoisomerase I inhibitor that interferes with DNA replication by stabilizing the complex between topoisomerase I and DNA, leading to lethal double-stranded DNA breaks and apoptosis. Docetaxel is a taxoid antineoplastic agent that promotes microtubule assembly and stabilizes them against depolymerization, disrupting cell division and inducing cell death. The combination has shown synergistic effects in preclinical studies, particularly when docetaxel is administered before irinotecan[1][6]. Both drugs are approved for use as single agents in various cancers; their combination has been investigated in clinical trials for advanced esophageal cancer and other solid tumors[1][6].
- Other names
- docetaxel and irinotecan
02
Targets
TOP1 (DNA Topoisomerase I)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on irinotecan + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan + docetaxel.